TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02922686
Drug: Placebo (for phenoxymethylpenicillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
Study: NCT00437294
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily, 21-day cycles until progressive disease
Study: NCT00437294
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
Study: NCT01646268
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches
Study: NCT02933684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in pill form.
Study: NCT03364270
Drug: PET/CT Imaging with [F-18] RGD-K5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
Study: NCT04364984
Drug: Angiotensin converting enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine drug intake
Study: NCT04364984
Drug: Direct renin inhibitor
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine drug intake
Study: NCT01307189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diskus inhalation powder, once daily
Study: NCT02105961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9percent sodium chloride solution
Study: NCT00461591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Study: NCT02467426
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarterial infusion of cisplatin and mithoxantrone
Study: NCT02660489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03248791
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
Study: NCT00852839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match oromucosal formulation of 552-02
Study: NCT00961909
Drug: RO5095932
Approvals — FDA: no, EMA: no, PMDA: no
Description: cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
Study: NCT00961909
Drug: RO5095932
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose titration to target dose, sc once weekly for 6 weeks
Study: NCT00961909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc once weekly for 4 weeks
Study: NCT01528839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00322517
Drug: SU014813
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsule/day for 6 cycle of 21 days
Study: NCT00008034
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01711424
Drug: OPTIVE PLUS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
Study: NCT01700387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
Study: NCT02481453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator: placebo
Study: NCT01473602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT00531427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal system (placebo) applied for 7-day wear
Study: NCT00006289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tabs b.i.d.
Study: NCT00006289
Drug: Neurotropin
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tabs b.i.d.
Study: NCT03254511
Drug: Chemotherapeutic Combinations
Normalized name: ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
Study: NCT02110459
Drug: POL7080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04120519
Drug: thalidomide combined with dexamethasone and cyclophosphamide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TCD
Study: NCT02439489
Drug: BKM120-CARBO
Normalized name: CARBO ANIMALIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
Study: NCT00692263
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
Study: NCT03190941
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study: NCT00859352
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets during 14 consecutive days.
Study: NCT02605460
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
Study: NCT01783756
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03645434
Drug: AZD8871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
Study: NCT03645434
Drug: Anoro® Ellipta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
Study: NCT03678649
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
Study: NCT02154152
Drug: Homoeopathic Medicine causticum 200c
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02422199
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00758199
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
Study: NCT00758199
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
Study: NCT00003496
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02529553
Drug: LY3076226
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02605122
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age- and weight-based dosing as appropriate per sites standard of care.
Study: NCT00667108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT02923921
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX Alone
Study: NCT04606329
Drug: LuminoMark inj.(Conc. for fluorescence)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Study: NCT04606329
Drug: Charcotrace Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Study: NCT02558413
Drug: BTA-C585 oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTA-C585; Single ascending doses from 50 mg to 800 mg
Study: NCT02558413
Drug: BTA-C585 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses to match 50 to 800 mg BTA-C585 capsules
Study: NCT01250145
Drug: LY333334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch
Study: NCT01250145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch
Study: NCT04475042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04384081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04316091
Drug: neoadjuvant chemotherapy+SPIONs/SMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
Study: NCT01587807
Drug: GSK1995057
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled dose (volume based on cohort)
Study: NCT01587807
Drug: LPS
Normalized name: ALPS LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg
Study: NCT01587807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
Study: NCT00947687
Drug: PUR003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
Study: NCT00947687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05764707
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
Study: NCT05764707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will received 1000mg of normal saline within 30 minutes of skin closure.
Study: NCT03223519
Drug: Comboprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
Study: NCT03223519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution administered TID for 3 days
Study: NCT03223519
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Powder for oral solution administered TID for 3 days
Study: NCT04155580
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT04155580
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT01485172
Drug: placebo monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo as monotherapy in Parkinson's disease
Study: NCT02428283
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 1 μg/kg was injected before skin incision.
Study: NCT00050362
Drug: Rofecoxib and Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00495014
Drug: GSK376501
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00495014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02049606
Drug: CENATONE tablet
Normalized name: BENTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Tablets once a day
Study: NCT02907632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
Study: NCT03143933
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02594254
Drug: C16G2 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial peptide
Study: NCT00133549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.
Study: NCT03801031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Study: NCT00560573
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
Study: NCT00726882
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment in prior ABT-333 studies.
Study: NCT00347776
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral antibiotic
Study: NCT00347776
Drug: topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01788969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent + training vs Placebo + training
Study: NCT03615040
Drug: MSTT1041A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2.
Study: NCT03615040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
Study: NCT01776307
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI608 is administered at 500 mg po bid continuously.
Study: NCT01776307
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
Study: NCT00866697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Study: NCT02577601
Drug: Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00007813
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04004871
Drug: Nab-paclitaxel, Cisplatin and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
Study: NCT00573144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 72 hours of saline solution (packaged to match active comparator)
Study: NCT02546700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously once in every 4 weeks.
Study: NCT03735680
Drug: ONM-100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A polymer micelle covalently conjugated to indocyanine green.
Study: NCT01639729
Drug: Treatment A: Sufentanil IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Study: NCT01422876
Drug: high dose FDC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT01639729
Drug: Treatment B: Sufentanil NanoTab Sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Study: NCT01639729
Drug: Treatment C: Sufentanil NanoTab Buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Study: NCT01639729
Drug: Treatment D: Sufentanil NanoTab Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Sufentanil NanoTab 15 mcg swallowed (PO)
Study: NCT01422876
Drug: low dose FDC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02641340
Drug: Fentanyl Sublingual Spray
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
Study: NCT01422876
Drug: high dose BI 10773 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02641340
Drug: Fentanyl Citrate IV
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Citrate 50 mcg, delivered intravenously
Study: NCT01422876
Drug: BI 10773 low dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT01422876
Drug: low dose BI 10773 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT01015638
Drug: Clindamycin and BPO 5% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
Study: NCT01015638
Drug: Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
Study: NCT01905631
Drug: Aurstat Anti-Itch Hydrogel (Aurstat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
Study: NCT04220073
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00299546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections
Study: NCT03404024
Drug: Stage 2-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
Study: NCT00863213
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
Study: NCT01090323
Drug: ICL670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
Study: NCT03514446
Drug: Antibiotic therapy duration for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy for seven days
Study: NCT01766505
Drug: Candemore tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure.
Study: NCT03842202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once weekly injections of semaglutide matched placebo.
Study: NCT00460421
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose etoposide, Cyclophosphamide
Study: NCT00711477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03043105
Drug: Thalidomide, cyclophosphamide and prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year.
Study: NCT00743106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
Study: NCT02194374
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
Study: NCT00799214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study: NCT03386838
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)